

Market Announcement

15 November 2019

HeraMED Limited (ASX: HMD) – Trading Halt

Description

The securities of HeraMED Limited ('HMD') will be placed in trading halt at the request of HMD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 19 November 2019 or when the announcement is released to the market.

Issued by

Madeleine Green

Senior Adviser, Listings Compliance (Perth)



15 November 2019

Madeleine Green
Senior Adviser, Listings Compliance
ASX Operations
Level 40 Central Park
152-158 St George's Terrace
PERTH WA 6000

Via Email: tradinghaltsperth@asx.com.au

Dear Ms Green

TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, HeraMED Limited (Company) hereby requests that its securities be placed into an immediate trading halt pending a response to a follow up by the ASX on the price and volume query of 14 November 2019.

The Company requests that trading in its securities be halted until after the expected announcement is made regarding the above or until the market opens on Tuesday, 19 November 2019, whichever is the earlier.

The Company is not aware of any reason why this trading halt request should not be granted.

Yours sincerely

A handwritten signature in blue ink, appearing to read "Stephen Buckley".

Stephen Buckley
Company Secretary

About HeraMED Limited (ASX:HMD):

HeraMED Limited is an innovative medical technology company delivering smart pregnancy monitoring solutions for home and professional use. HeraMED provides peace of mind to expecting parents by solving problems associated with the reliability of pre-natal analysis, as well as the cost and shortage in fundamental services through end-to-end medical grade solutions utilising monitoring devices, cloud based platforms and AI capabilities.

HeraMED is commercialising the worlds most advanced, smart medical grade ultrasound monitoring device HeraBEAT. The device has passed multiple clinical trials and secured approval by key regulatory bodies including TGA (Australia), CE (Europe) and AMAR (Israel) for commercial sale.

The Company has partnerships with two leading medical organisations, the Mayo Clinic and TEVA Pharmaceutical Industries Inc. (NYSE: TEVA). HeraMED diversifying its product range and services with the launch of SaaS services and cloud based monitoring systems.